Volume 10, Number 11—November 2004
Research
Evaluating Human Papillomavirus Vaccination Programs
Al V. Taira*, Christopher P. Neukermans†, and Gillian D. Sanders†‡
Table 2
Total discounted healthcare costs, total discounted life expectancy in years, and total quality-adjusted discounted lifetime expectancy in years are presented for prevaccination, and for female-only and male + female vaccination scenarios.
| Outcome | No vaccination | HPV-16/18 vaccination |
|
|---|---|---|---|
| Female-onlya | Female + maleb | ||
| Cost, $ | 40,423 | 40,667 | 40,929 |
| Incremental cost, $ | 244 | 261 | |
| Life expectancy, y | 28.7975 | 28.8112 | 28.8117 |
| Incremental life expectancy, d | 5.0 | 0.18 | |
| Quality-adjusted life expectancy, y | 27.7422 | 27.7590 | 27.7596 |
| Incremental quality-adjusted life expectancy, d | 6.1 | 0.21 | |
| Incremental cost-effectiveness | |||
| $ per life-year | 17,802 | 534,317 | |
| $ per quality-adjusted life-year | 14,583 | 442,039 | |
| % reduction in lifetime cervical cancer cases | 61.8 | 2.2 | |
aIncremental to no vaccination strategy.
bIncremental to a female-only vaccination strategy.
